Discontinued psychiatric drugs in 2008

  title={Discontinued psychiatric drugs in 2008},
  author={Victoria D Kirchhoff and Ha T T Nguyen and Joanna K Soczynska and Hanna O. Woldeyohannes and Roger S. McIntyre},
  journal={Expert Opinion on Investigational Drugs},
  pages={1431 - 1443}
During the past several decades, neuropsychiatric agents have been one of the fastest growing classes of medicinal agents. This expansion is in part due to the increased recognition of the prevalence and burden of illness associated with disparate neuropsychiatric disorders, increased public awareness and possibly reduced stigma associated with mental illness, as well as extensive marketing of neuropsychiatric agents to healthcare providers. Most of the agents reviewed herein represent… 

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Preclinical and clinical results for neuropeptide receptor ligands that have been studied in clinical trials for psychiatric diseases, including agents that target the receptors for tachykinins, corticotropin-releasing factor, vasopressin and neurotensin are analyzed and new ways to exploit the full potential of these candidate drugs are suggested.

Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists

The role of OT and AVP in neuropsychiatric conditions, as well as the findings of different OT-R and A VP-R agonists and antagonists, used both at the preclinical and clinical level are summarized.

Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function

The data on how SSRIs and vortioxetine, an antidepressant with multimodal activity, affect hippocampal function, including cognitive processing, from both a preclinical and clinical perspective is reviewed.

The Corticotropin-Releasing Factor Family: Physiology of the Stress Response.

This review focuses on the physiology of CRF-related peptides and their cognate receptors and describes the major molecular features covering aspects of gene expression and regulation, structural properties, and molecular interactions, as well as mechanisms of signal transduction and their surveillance.

Vasopressin V1a and V1b receptor modulators: a patent review (2012 – 2014)

  • M. Ślusarz
  • Biology
    Expert opinion on therapeutic patents
  • 2015
This paper describes the compounds from the patents along with their biological activity of vasopressin V1a and V1b receptors and focuses on the oxindole derivatives, which appear to be the most promising drug candidates.

Looking back (and in)to the future: A personal reflection on ‘Serotonin autoreceptor function and antidepressant drug action’ (Hjorth et al., 2000)

  • S. Hjorth
  • Biology, Psychology
    Journal of psychopharmacology
  • 2016
The results were summarised of rat microdialysis studies carried out to examine the relative importance of 5-HT1A and 5- HT1B autoreceptors, including possible regional variation, and potential changes in autoreceptor responsiveness following chronic selective serotonin reuptake inhibitor administration.

The vasopressin Avprlb receptor: Molecular and pharmacological studies

The Avpr1b KO also appears to be an excellent model to study the contribution of the AvPR1b in the HPA axis response to acute and perhaps some chronic (repeated) stressors where corticotrophin-releasing hormone and other genes involved in theHPAaxis response to stress do not appear to compensate for the loss of theAvpr1B.

Biotransformation and bioactivation reactions of alicyclic amines in drug molecules

The current review provides a comprehensive summary of biotransformation and bioactivation pathways of aliphatic nitrogen containing heterocycles and strategies to mitigate metabolic liabilities.



Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD.

A history of psychosis, age at onset, bipolar I versus II subtype, history of rapid cycling, prior hospitalizations, current illness state, and history of alcohol or substance use disorders did not significantly alter the risk profiles for receiving complex regimens.

The hepatic safety profile of duloxetine: a review.

Duloxetine does not appear to pose a greater hazard for hepatic toxicity when compared to other conventional antidepressants and systematic monitoring of liver aminotransferases does not seem to be warranted with routine duloxettine use.

The dexamethasone suppression test in patients with mood disorders.

The RDC endogenous/nonendogenous dichotomy was validated by the DST and the Research Diagnostic Criteria (RDC) primary/secondary and Winokur and colleagues' family history subtypes for unipolar depression were not strongly validated.

Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment

Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats

The hypothesis that ZNS may effectively treat or prevent weight gain or metabolic changes associated with the SGAs suggests that this combination might be beneficial when co-administered with OLZ.

Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator.

  • A. LippaP. Czobor P. Skolnick
  • Psychology, Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2005
It is reported that the pyrazolo[1,5-a]-pyrimidine, ocinaplon, exhibits an anxioselective profile in both preclinical procedures and in patients with generalized anxiety disorder, the most common of the anxiety disorders.

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders

Findings point to a role for vasopressin in the modulation of emotional processes via the V1b receptor, and suggest that its blockade may represent a novel avenue for the treatment of affective disorders.

Mechanisms of Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIA 2-024

The available data indicate that the anticonvulsant efficacy of these AEDs is mainly due to the inhibition of sodium channel activity, which is in line with previous reports on these drugs.